


2024 HIV and Hepatitis Prevention Program Snapshot

Program-Supported HCV Screening

The HIV and Hepatitis Prevention Program partners with a variety of stakeholders to support strategic implementation of hepatitis C (HCV) testing services across Iowa. In 2024, 15,855 rapid and conventional HCV tests were administered in partnership with 80 partners across five major settings (an increase of 37% from 2023).

- **12 Integrated Testing Services (ITS) Agencies** providing clinical and outreach testing to people with a history of injection drug use;
- **31 Federally Qualified Health Center (FQHC) Locations** working to implement routine screening across 11 agencies in partnership with the Iowa Primary Care Association;
- **14 Substance Use Treatment locations** integrating HCV screening into medically assisted treatment programs;
- **22 Community-based Screening Services (CBSS) projects** working with Iowa HHS to provide safety-net STI screening services; and
- **12 State Disease Intervention Specialists** providing free rapid and confirmatory HCV testing to individuals engaged in HIV partner services.

Total Program HCV Testing & Positivity 2024



Across all projects, the program reported a **1.35% total positivity rate in 2024**, a decrease from the 2023 rate of 2.33%

Substance use treatment settings delivering medication for opioid use disorder (MOUD) had the highest positivity rate reported at 6.1%. This can be attributed to the prevalence of HCV transmission among people who use injection drugs (PWID) and the increased likelihood that PWID will be encountered in settings that provide MOUD and other treatments for substance use disorders.

Data are not de-duplicated. Numbers represent test encounters not unique individuals.